← All organizations
Highest phase reached
Phase 4
First clinical trial
Nov 1, 1998First marketed drug
May 5, 2004First NDA
May 5, 2004Last known activity
Jun 1, 2012
Acquired by Bausch & Lomb → Bausch Health Companies on Jan 1, 2012
Timeline
1990s
- Jan 1, 1992
ISTA Pharmaceuticals— Founded
2000s
- Mar 24, 2005
bromfenac— NDA Organization
2010s
- Jan 1, 2012
Bausch & Lomb— Acquired By
- Aug 6, 2013
Drugs by trial phase (9 distinct, 29 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (2 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Cataract
- Conjunctivitis
- Conjunctivitis, Allergic
- Diabetic Retinopathy
- Dissociative Disorders
- Drug Hypersensitivity
- Dry Eye Syndromes
- Eye Diseases
- Eye Infections
- Hemorrhage
- Hypersensitivity
- Inflammation
- Keratoconjunctivitis Sicca
- Postoperative Complications
- Retinal Diseases
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Syndrome
- Vitreous Detachment
- Vitreous Hemorrhage
Marketed drugs (3)
Recent trials (29)
- NCT01650584Study directorN/AJun 1, 2012
- NCT01578278Study directorPhase 2Dec 1, 2011
- NCT01367249Study directorPhase 3May 1, 2011
- NCT01277341Study directorPhase 2Dec 1, 2010
- NCT01212471Study directorPhase 3Sep 1, 2010
- NCT01174823Study directorPhase 2Jun 1, 2010
- NCT01222299Study directorPhase 1/Phase 2May 1, 2010
- NCT00854061Study directorPhase 3Feb 1, 2009
- NCT00853970Study directorPhase 3Feb 1, 2009
- NCT00758784Study directorPhase 2Aug 1, 2008
- NCT00699803Study directorPhase 2May 1, 2008
- NCT00667004Study directorPhase 2Apr 1, 2008
- NCT00586664Study directorPhase 3Oct 1, 2007
- NCT00586625Study directorPhase 3Oct 1, 2007
- NCT00585975Study directorPhase 2Oct 1, 2007
Details
- Founded
- Irvine, CA, US Jan 1, 1992
- First NDA
- May 5, 2004
- Last known activity
- Jun 1, 2012
Designations held
- Priority review